Media

WELCOME TO THE FINAL EVENT OF THE BUSINESS INTEGRITY MONTH UNIC 2020
09 december, 2020
Events

December 15 at 16:00 - Webinar for business owners and СЕОs 'Investigation of Ukrainian cases in the USA – corruption or policy?' Free registration: https://bit.ly/2Li01AO

More
TOMORROW - 10 Dec - HIGH LEVEL EVENT
09 december, 2020
Events

Business initiatives that change the world. Collective action initiatives – development of coalition against corruption Free registration: https://bit.ly/36YT3sT

More
Network held its first meeting with the Independent Association of Banks of Ukraine
23 november, 2020
News

We are pleased to announce that last week the Network held its first meeting with the Independent Association of Banks of Ukraine.

More
Discussion on “Reforming the State Tax Service through the Prism of Integrity of Taxpayers and Taxpayers”
16 november, 2020
News

On November 12, 2020, a high-level discussion on “Reforming the State Tax Service through the Prism of Integrity of Taxpayers and Taxpayers” organized by the Ukrainian Network of Integrity and Compliance (UNIC) took place.

More
JOIN THE EVENT WITHIN THE UNIC BUSINESS INTEGRITY MONTH
12 november, 2020
Events

November 19, 11:00 - 12:30 Frank discussion with CEOs of Ukrainian and international businesses on typical compliance risks of Ukrainian business. Based on practical experience from auditing companies.

More
JOIN UNIC AT THE HIGH LEVEL DISCUSSION
11 november, 2020
Events

Reforming the State Tax Service through the lenses of the tax officers and taxpayers integrity November 12, 16:00 – 17:30

More
UNIC WELCOMES THE NEW MEMBER: SERVIER
28 october, 2020
News

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests in average 25% of its turnover (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More
09 october, 2020
News